FDA cited Tom's of Maine for CGMP failures after finding objectionable microbes in water and toothpaste and inadequate complaint handling.
What happened
FDA inspected the Sanford, Maine, drug manufacturing facility from May 7 to 22, 2024. The agency found Pseudomonas aeruginosa and Ralstonia insidiosa in water used to make and clean OTC toothpastes, Paracoccus yeei in a finished toothpaste batch, black mold-like substance and powder residues near product-contact equipment, and about 400 odor, color, and taste complaints that were not investigated. FDA said the company's responses were inadequate.
What FDA found
The firm failed to follow adequate written procedures to prevent objectionable microorganisms; Pseudomonas and Ralstonia were found in water and Paracoccus in finished toothpaste, and product impact was not adequately investigated.
21 CFR 211.113(a)The firm did not adequately qualify its water system; the qualification lacked total organic carbon, conductivity, and gram-negative microorganism analysis.
21 CFR 211.113(a)The firm failed to maintain buildings in good repair; FDA observed black mold-like substance near product-contact equipment and powder residues on a tray before raw materials were added.
21 CFR 211.58The firm's complaint procedure was inadequate; about 400 odor, color, and taste complaints, including for children's toothpaste, were not investigated.
21 CFR 211.198(a)
What FDA wants
FDA asks the company to respond in writing within 15 working days with corrective actions and to provide comprehensive assessments, investigations, risk assessments, microbial specifications and testing, water-system remediation, cleaning assessment, and complaint-system remediation. If corrective actions cannot be completed in that time, the company must state why and give a completion schedule.
Who should pay attention
- retailers and distributors selling Tom's of Maine OTC toothpastes
- contract manufacturers of OTC oral care products
- quality teams managing pharmaceutical water and cleaning systems
This is a summary. Read the original letter on fda.gov.